31st week of 2011 patent applcation highlights part 38 |
Patent application number | Title | Published |
20110189164 | Peptide Stabilizer Compounds and Screening Method - Peptide stabilizer compounds are provided that in combination with a biologically active peptide, can increase the protease elimination half-time of the biologically active peptide in vivo. The peptide stabilizer compounds are preferably in the form of peptide sequences that confer resistance to proteolysis upon conjugated biologically active peptides. Also provided is a method for the selection of novel proteolysis resistant compounds from in vitro generated libraries, and pharmaceutical compositions comprising the stabilizer compounds identified thereby. | 2011-08-04 |
20110189165 | METHOD OF IDENTIFYING DISEASE RISK FACTORS - Provided herein is a method for identifying a genetic variant that is associated with development of a condition of interest (e.g., Alzheimer's disease), and genetic variants so identified. Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein. In some embodiments, the genetic variant is a deletion/insertion polymorphism (DIP) of the TOMM40 gene. Kits for determining if a subject is at increased risk of developing late onset Alzheimer's disease is also provided. Kits for determining if a subject is responsive to treatment for a condition of interest with an active agent are further provided. | 2011-08-04 |
20110189166 | METHODS OF TREATING HEMORHEOLOGIC ABNORMALITIES IN MAMMALS - Methods of treating hemorheologic abnormalities in mammals are provided, as well as methods of evaluating circulatory flow mechanics by analyzing hemorheologic determinants or hemorheologic abnormalities in the blood. | 2011-08-04 |
20110189167 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases - Methods of modulating a kinase activity of a wild-type kinase species, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs of any of the foregoing, are provided which employ compounds of the formula Ia: | 2011-08-04 |
20110189168 | ANTIBODY-INDUCED APOPTOSIS - Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions. | 2011-08-04 |
20110189169 | COMBINATION OF HGF INHIBITOR AND PTEN AGONIST TO TREAT CANCER - The present invention is directed toward a method of treating cancer by administering to a patient an inhibitor of Hepatocyte Growth Factor and an agonist of PTEN. | 2011-08-04 |
20110189170 | Chimeric Anti-VEGF-D Antibodies and Humanized Anti-VEGF-D Antibodies and Methods of Using the Same - The present invention relates to materials and methods for modulating angiogenesis and lymphangiogenesis. The compositions of the invention provide chimeric and/or humanized VEGF-D antibody substances, antibodies, polypeptides and fragments thereof useful for modulating angiogenesis and lymphangiogenesis in a subject. | 2011-08-04 |
20110189171 | RECOMBINANT ANTIBODIES FOR TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS - Disclosed are novel polyclonal antibodies, which target respiratory syncytial virus (RSV), as well as novel high affinity antibody molecules reactive with RSV. The polyclonal antibodies may comprise antibody molecules which are reactive with both RSV protein F and RSV protein G, and preferably the polyclonal antibodies target a variety of epitopes on these proteins. The antibody molecules of the invention have shown superior efficacy in vitro and/or in vivo. Also disclosed are methods of producing the antibodies of the invention as well as methods of their use in treatment or prevention of RSV infection. | 2011-08-04 |
20110189172 | METHODS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS - Disclosed are compositions and methods for the treatment and/or prevention of rheumatoid arthritis, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof. | 2011-08-04 |
20110189173 | PHOSPHORYLATED C-ErbB2 AS A SUPERIOR PREDICTIVE THERANOSTIC MARKER FOR THE DIAGNOSIS AND TREATMENT OF CANCER - The present invention provides reliable methods to identify subsets of subjects with a cancer of epithelial origin characterized by a high level of phosphorylated c-erbB2 which does not correlate with the over-expression of total c-erbB2 as measured by IHC or FISH, for selection and inclusion for c-erbB2-direct treatment and therapy. Furthermore, the present invention provides a reliable method to determine whether a subject with a cancer of epithelial origin who has been determined to be c-erbB2 positive by IHC and by FISH should be excluded from c-erbB2-direct treatment because of a non-significant level of phosphorylated c-erbB2 in epithelial tumor tissue. | 2011-08-04 |
20110189174 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR INHIBITING PROGRESSION OF, PATHOGENIC OCULAR NEOVASCULARIZATION - A composition for treating, reducing, ameliorating, alleviating, or inhibiting the progression of, pathological ocular neovascularization comprises an integrin or vitronectin receptor antagonist having any one of Formulae I-XI, as defined herein. The composition can further comprise a VEGF inhibitor. Such composition is administered to an ocular environment by a method such as topical application, periocular injection, intravitreal injection, or intravitreal implantation. The composition can be administered alone or in combination with another procedure chosen to enhance the outcome of the treatment. | 2011-08-04 |
20110189175 | CHRONIC LYMPHOCYTIC LEUKEMIA PROGNOSIS AND TREATMENT - Provided herein are methods for identifying a subject afflicted with chronic lymphocytic leukemia who is responsive to treatment with a chemotherapeutic agent by detecting the presence or absence of at least one APOE4 allele in the subject, the presence of an APOE4 allele identifying the subject as responsive to the treatment. Also provided are methods of treating a subject afflicted with chronic lymphocytic leukemia, including administering an estrogenic agent, an androgen withdrawal agent, an apoE4 peptide or mimetic thereof, and/or a chemotherapeutic agent in an amount effective to treat said chronic lymphocytic leukemia. Methods of determining a prognosis for a patient diagnosed with chronic lymphocytic leukemia are also provided. In addition, methods for stratifying a subject into a subgroup of a clinical trial and methods for identifying a patient in a clinical trial of a treatment for chronic lymphocytic leukemia are herein provided. | 2011-08-04 |
20110189176 | METHODS OF TREATING DISEASES WITH DLL4 ANTAGONISTS - The present invention provides methods of preventing, treating or ameliorating diabetes by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists that block Dll4-Notch signal pathways. As observed in a mouse model of diabetes, Dll4 antagonists exhibit protective effects on pancreatic islets, lower blood glucose levels, and block the production of auto-antibodies, including those against insulin and glutamic acid decarboxylase 65 (GAD65), via the expansion of regulatory T cells (Tregs). Thus, the present invention further provides methods of lowering the levels of blood glucose, and/or reducing or blocking the production of auto-antibodies, by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists. Suitable Dll4 antagonists for the invention include antibodies or antibody fragments that specifically bind Dll4 and block Dll4-Notch interactions, the extracellular domain of Dll4, and the like. | 2011-08-04 |
20110189177 | ANTIBODIES TO VLA-1 - Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures. | 2011-08-04 |
20110189178 | Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions - The present application relates to therapeutic moieties displaying reduced immunogen response, particularly for therapeutic purposes. | 2011-08-04 |
20110189179 | Identification of Tumor-Associated Antigens for Diagnosis and Therapy - The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases. | 2011-08-04 |
20110189180 | ANTIGENIC COMPOSITIONS AND USE OF SAME IN THE TARGETED DELIVERY OF NUCLEIC ACIDS - Methods and compositions are provided for delivery of therapeutic nucleic acids to a target cell. A chimeric antigen is provided to encapsulate, bind, or otherwise carry a nucleic acid molecule to a target cell where the chimeric antigen and nucleic acid are internalized by receptor-mediated endocytosis. The chimeric antigen has a nucleic acid interaction domain, a target binding domain, and an immune response domain that may include a target antigen. Targeting is generally provided by the specificity of the target binding domain for a particular target cell receptor, but may also be provided by inclusion of a targeting antigen within the immune response domain. The combined delivery of chimeric antigen and nucleic acid, which may be a siRNA, may be synergistic in certain applications, for example in breaking host tolerance to a virus or in providing immunostimulation. | 2011-08-04 |
20110189181 | Use of agents derived from CEACAM1 for the treatment of inflammatory diseases - The use of an agent that selectively modulates cross-linking of biliary glycoprotein polypeptides for the preparation of a pharmaceutical composition for preventing or treatment of a mammal subject afflicted with an inflammatory disease is provided. In particular, a method for preventing or treatment of a mammal subject afflicted with rheumatoid arthritis or multiple sclerosis, comprising the step of administering to a mammal in need thereof a therapeutic effective amount of a fusion protein of a fragment of biliary glycoprotein and a fragment of an immunoglobulin is described. | 2011-08-04 |
20110189182 | PROTEOLYTICALLY CLEAVABLE FUSION PROTEINS WITH HIGH MOLAR SPECIFIC ACTIVITY - The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV. | 2011-08-04 |
20110189183 | Antibodies against candida, collections thereof and methods of use - Provided herein are antibodies that immunospecifically bind to species of the genus | 2011-08-04 |
20110189184 | MODULATION OF NEURAL STEM CELLS AND NEURAL PROGENITOR CELLS - The invention relates generally to methods of influencing central nervous system cells to produce progeny useful in the treatment of CNS disorders. More specifically, the invention includes methods of exposing a patient suffering from such a disorder to a reagent that modulates the proliferation, migration, differentiation and survival of central nervous system cells via S1P or LPA signaling. These methods are useful for reducing at least one symptom of the disorder. | 2011-08-04 |
20110189185 | Method for Predicting Responsiveness to a Treatment With an Anti-HER2 Antibody - The invention provides an in vitro method for predicting whether a patient would be responsive to a treatment with an anti-HER2 blocking agent, such as trastuzumab, which method comprises determining the expression level of at least 4 genes in a biological sample of said patient, wherein said genes are GPR22, PEX19, GRHL2 and DERL1. The invention further provides a DNA chip for performing such method. | 2011-08-04 |
20110189186 | AFFECTING BONE RELATED CONDITIONS USING CD68 BLOCKING AGENTS - Methods of treating, reducing, and/or preventing cancer metastasis to bone using CD68 blocking agents are provided. For example, the methods can be used to reduce breast cancer metastasis to bone. Also provided are methods of treating, reducing, and/or preventing bone resorption in a subject using CD68 blocking agents. For example, the methods can be used to treat osteoporosis. | 2011-08-04 |
20110189187 | Novel immunogenic compositions for the prevention and treatment of meningococcal disease - The present invention relates to | 2011-08-04 |
20110189188 | NOVEL GP96 DERIVED PEPTIDES - Provided is a gp96-derived peptides or homologs or derivatives thereof, pharmaceutical composition including them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins including them. | 2011-08-04 |
20110189189 | COMBINATION OF CD137 ANTIBODY AND CTLA-4 ANTIBODY FOR THE TREATMENT OF PROLIFERATIVE DISEASES - Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. | 2011-08-04 |
20110189190 | ANTI-HEPCIDIN-25 SELECTIVE ANTIBODIES AND USES THEREOF - Monoclonal antibodies are provided that bind to the N-terminus of human hepcidin-25 and are characterized as having high affinity and selectivity for the polypeptide. The antibodies of the invention are useful for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment of various disorders, such as anemia, in a human subject. The antibodies of the invention are also useful as analytical tools, such as in sandwich ELISA. | 2011-08-04 |
20110189191 | Methods and Compositions for Treating Conditions of the Eye - Provided are methods and compositions for treating ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of, for example, a photodynamic therapy (PDT)-based approach can be enhanced by combining the PDT with an anti-FasL factor, for example, an anti-FasL neutralizing antibody. | 2011-08-04 |
20110189192 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS - Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, and solvates thereof. Q is a tetrahydropyridinyl ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0. | 2011-08-04 |
20110189193 | CELL LINES AND HOST NUCLEIC ACID SEQUENCES RELATED TO INFECTIOUS DISEASE - Host nucleic acids and host proteins that participate in viral infection, such as human immunodeficiency virus (HIV), influenza A, and Ebola virus, have been identified. Interfering with or disrupting the interaction between a host nucleic acid or host protein and a virus or viral protein confers an inhibition of or resistance to infection. Thus, interfering with such an interaction in a host subject can confer a therapeutic or prophylactic effect against a virus. The sequences identified can be used to identify agents that reduce or inhibit viral infection. | 2011-08-04 |
20110189194 | USE OF CD95 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The present invention refers to the use of an inhibitor of the CD95/CD95L system for the prevention and/or treatment of an inflammatory disorder or for the prevention and/or treatment of an inflammatory process in a neuronal disorder, particularly in a CNS disorder. | 2011-08-04 |
20110189195 | METHOD FOR CONTROLLING CANCER METASTASIS OR CANCER CELL MIGRATION BY MODULATING THE CELLULAR LEVEL OF LYSYL TRNA SYNTHETASE - The present invention relates to a novel function of lysyl tRNA synthetase (KRS) which enhances tumor cell migration and affects cancer metastasis via KRS's interaction with laminin receptor (67LR) by its translocation to membrane. More particularly, the present invention relates to a method for modulating cancer metastasis or migration, which comprises regulating intracellular levels of KRS; a composition for preventing or treating cancer; use of expression vector for inhibiting the expression of KRS; a method for preventing or treating cancer; use of an agent for inhibiting an activity of KRS; a method for screening an agent which modulates cancer metastasis or migration; and a method for screening an agent which inhibits the interaction of KRS with 67LR, by said novel function. Thus, KRS can modulate cancer metastasis or migration and furthermore, can modulate intra-cellular metabolism related to 67LR. The interaction between KRS and 67LR can be used effectively in treating, preventing and/or diagnosing of various diseases or disorders related to the interaction. | 2011-08-04 |
20110189196 | METAL-CITRATE TRANSPORTER ANTIGEN FROM STREPTOMYCES COELICOLOR AND USES THEREOF - The present invention relates to an isolated antigen from | 2011-08-04 |
20110189197 | Antibodies Against Protective Antigen - The present invention relates to antibodies and related molecules that specifically bind to protective antigen of | 2011-08-04 |
20110189198 | Compositions and Methods for Diagnosing and Treating an Inflammation - An isolated polypeptide is provided. The polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein the antigen recognition domain comprises at least three CDR amino acid sequences selected from the group consisting of SEQ ID NO: 11, 15, 19, 23, 27 and 31. Also provided are compositions which comprise the peptide and uses of same. | 2011-08-04 |
20110189199 | METHODS FOR P2RY5 MEDIATED REGULATION OF HAIR GROWTH AND MUTANTS THEREOF - The invention provides for a method for screening compounds that bind to and modulate the hair-specific G-protein coupled receptor, P2RY5. The invention further provides for methods for controlling hair growth by administering a P2RY5 modulating compound to a subject. | 2011-08-04 |
20110189200 | METHODS OF TREATING AUTOIMMUNE DISEASES WITH DLL4 ANTAGONISTS - The present invention provides methods of treating a disease or disorder, in which increasing the number of regulatory T cell (Treg) is beneficial, by administering to a subject suffering from such a disease or disorder a therapeutically effective amount of DII4 antagonists that block DII4-Notch signal pathways, thereby increasing the number of Treg. Diseases or disorders treatable by the methods of the invention include autoimmune diseases or disorders, such as multiple sclerosis (MS), diabetes, and the like. Suitable DII4 antagonists for the invention include antibodies or antibody fragments that specifically bind DII4 and block DII4-Notch interactions, the extracellular domain of DII4, and the like. The invention also provides methods of preventing an occurrence or recurrence of such diseases or disorders in a subject predisposed or susceptible to developing such diseases or disorders. Furthermore, the methods of the invention are useful in preventing or treating organ transplant rejections or graft-versus-host disease. | 2011-08-04 |
20110189201 | MODULATION OF BONE DEVELOPMENT - Methods and compositions for modulating bone development are described. | 2011-08-04 |
20110189202 | COMPOSITIONS COMPRISING SOLUBLE CD84 OR ANTI-CD84 ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING B-CLL - A method of diagnosing B-CLL in a subject in need thereof is provided. The method comprising determining in a biological sample of the subject a level of CD84 isoform C (SEQ ID NO: 30), wherein an increase in the level of the CD84 isoform C (SEQ ID NO: 30) beyond a predetermined threshold with respect to a level of the CD84 in a biological sample from a healthy individual is indicative of the B-CLL. | 2011-08-04 |
20110189203 | IMMUNOGLOBULIN CONSTRUCTS - The present invention relates to protein and polypeptide constructs that comprise single variable domains that are linked to an Fc portion. The immunoglobulin constructs comprise two polypeptide chains in which each polypeptide chain comprises two or more single variable domains that are linked, usually via a suitable hinge region or linker, to one or more constant domains that, together, form an Fc portion. The invention also relates to polypeptide chains that form part of such constructs and/or that can be used to form such constructs. The invention further relates to nucleotide sequences and nucleic acids that encode or can be used to express such constructs or polypeptide chains; to methods for producing such constructs and polypeptides chains; to compositions (and in particular pharmaceutical compositions) that comprise such constructs or polypeptide chains; and to uses of such constructs, polypeptide chains or compositions. | 2011-08-04 |
20110189204 | Treatment of Disease with Proteasone Inhibitors - A method is provided for treating cancer in a patient comprising administering to said patient a proteasome inhibitor at least three days a week. | 2011-08-04 |
20110189205 | METHODS OF TREATING CANCER USING AN AGENT THAT MODULATES ACTIVITY OF THE CALCITONIN-GENE RELATED PEPTIDE ("CGRP") RECEPTOR - The present invention is directed to methods of treating cancer and preventing cancer metastasis in a subject by administering a modulator of CGRP receptor signaling. The present invention is further directed to methods of identifying novel compounds that inhibit CGRP receptor signaling, and reagents and animal models useful for the same. | 2011-08-04 |
20110189206 | Antibody Targeting Through a Modular Recognition Domain - Antibodies containing one or more modular recognition domains (MRDs) used to target the antibodies to specific sites are described. The use of the antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described. | 2011-08-04 |
20110189207 | METHODS FOR SOLUBLE ZALPHA11 CYTOKINE RECEPTORS - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block zalpha11 Ligand activity in vitro and in vivo, and may be used in conjunction with zalpha11 Ligand and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 2011-08-04 |
20110189208 | TB VACCINE - The invention relates to a vaccine useful in therapy and prevention of mycobacterial infections. | 2011-08-04 |
20110189209 | FOLD-BACK DIABODY DIPHTHERIA TOXIN IMMUNOTOXIN AND METHODS OF USE - Provided are methods and compositions related to diphtheria toxin diabody immunotoxins. | 2011-08-04 |
20110189210 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION - The present invention aims at provision of a method for inhibiting remnant lipoprotein production and a remnant lipoprotein production inhibitor, which includes administering a compound having a CETP inhibitory activity to an administration subject. The remnant lipoprotein production inhibitor of the present invention contains a compound having a CETP inhibitory activity as an active ingredient. | 2011-08-04 |
20110189211 | STEM CELL POPULATIONS AND METHODS OF USE - The present invention relates to populations of stem cells, methods for isolating these stem cell populations, and methods repairing, regenerating, and reconstituting tissues using the these stem cell populations. The invention additionally relates to methods of screening agents that promote growth, engraftment, or differentiation of stem cells. | 2011-08-04 |
20110189212 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS - Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided. | 2011-08-04 |
20110189213 | MYBL2 EPITOPE PEPTIDES AND VACCINES CONTAINING THE SAME - Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from MYBL2 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the MYBL2 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the MYBL2 polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention. The cancers to be targeted include, but are not limited to, testicular tumor, pancreatic cancer, bladder cancer, non-small cell lung cancer, small cell lung cancer and esophageal cancer. | 2011-08-04 |
20110189214 | CDCA1 EPITOPE PEPTIDES AND VACCINES CONTAINING THE SAME - Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from CDCA1 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the CDCA1 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the CDCA1 polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention. The cancers to be targeted include, but are not limited to, breast cancer, bladder cancer, esophageal cancer, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). | 2011-08-04 |
20110189215 | Vaccine Comprising Protein NMB0964 From Neisseria Meningitidis - The present invention relates to immunogenic compositions comprising neisserial blebs with upregulated levels of the NMB0964 antigens such that bacterial antibodies are generated against said antigen. Methods are also provided to upregulate expression through removal of the zinc repression mechanism of the cell or promoter or through removal of zinc from the culture medium. | 2011-08-04 |
20110189216 | Compositions and Methods for the Treatment and Prophylaxis of Multiple Strains and Subtypes of HIV-1 - A self-adjuvanting immunogenic composition comprising multiple immunogens, each immunogen comprising a lipopeptide cap, a universal T helper sequence and an immunodominant HIV-1 Tat B cell epitope. The immunogen also comprises one or more linker sequences and/or polar charged amino acid sequences. The HIV-1 Tat B cell epitope of each immunogen has an amino acid sequence of V-D-P-Xaa7-L-Xaa9-P-W-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-amide SEQ ID NO: 1, in which the amino acid positions at Xaa7, Xaa9 and Xaa12 are selected from specific amino acid residues choices and in which the amino acid positions at Xaa13-Xaa16 may be absent or specific amino acid residue choices. The lipopeptide is a dipalmitoyl-S-glyceryl-cysteine or a tripalmitoyl-S-glyceryl cysteine or N-acetyl (dipalmitoyl-S-glyceryl cysteine), each with an optional neutral amino acid linker. Optional polar sequences of at least four charged polar amino acids enhance solubility of the immunogen and are located at the carboxy terminal end of the lipopeptide cap, optionally flanked by neutral linker amino acids, or elsewhere in the immunogen. In the composition, each immunogen differs from another immunogen by an amino acid variation at amino acid position Xaa7, Xaa9 or Xaa12 of the immunodominant HIV-1 Tat epitope. Such compositions can induce anti-HIV-1 Tat antibodies with geometric mean titers of greater than 1,000,000 on multiple HIV-1 Tat variants, when employed to immunize a subject, without any extrinsic adjuvant. | 2011-08-04 |
20110189217 | METHODS AND MATERIALS FOR PRODUCING IMMUNE RESPONSES AGAINST POLYPEPTIDES INVOLVED IN ANTIBIOTIC RESISTANCE - This document relates to methods and materials for producing immune responses against polypeptides involved in antibiotic resistance. For example, vaccines against polypeptides involved in antibiotic resistance as well as methods for vaccinating mammals against polypeptides involved in antibiotic resistance are provided. | 2011-08-04 |
20110189218 | Plasmodium vivax hybrid circumsporozoite protein and vaccine - Described in this application is a synthetic | 2011-08-04 |
20110189219 | SIALIC ACID TO SUPPORT THE IMMUNE SYSTEM IN THE ELDERLY - The present invention generally relates to the field of the immune system, in particular to strengthening the immune system of the elderly. One embodiment of the present invention relates to the use of a food product enriched with sialic acid for the preparation of a composition to strengthen the immune system. | 2011-08-04 |
20110189220 | MUSHROOM COMPOSITIONS AND METHODS FOR MAKING AND USING - The present subject matter relates to a novel mushroom composition and methods for making and using the same. In one aspect, the subject matter involves a composition comprising a combination of mushrooms or components derived from mushrooms selected from the group consisting of Reishi | 2011-08-04 |
20110189221 | NOVEL ANTIVIRAL COMPOUNDS FROM MARINE EXTRACTS - The subject invention pertains to novel biologically active extracts from marine algae and to biologically active fractions and components of these extracts. These extracts have been shown to possess antiviral properties. Pharmaceutical compositions comprising these extracts, or comprising biologically active fractions or components of these extracts, could be used in the treatment of viral diseases including influenza. | 2011-08-04 |
20110189222 | COMPOSITION FOR WOUND HEALING - A composition to be orally administered and/or topically applied for enhancing wound healing, tissue repair and cardiovascular health protection comprising an extract of vegetative parts of Ipomoea, Arecaceae plant family and/or seaweeds through extraction using alcoholic solvent with or without combination with a co-solvent, which may be aqueous or organic as an active ingredient. | 2011-08-04 |
20110189223 | VACCINE - The present invention provides an immunogenic composition comprising an antigen or antigen composition and an adjuvant composition comprising an oil in water emulsion. | 2011-08-04 |
20110189224 | PESTIVIRUS REPLICONS PROVIDING AN RNA-BASED VIRAL VECTOR SYSTEM - The present invention concerns replicons of pestiviruses, in particular replicons of swine fever virus, engineered to have a defective replication thereby having lost infectivity, and further containing a foreign gene. A replicon of the invention contains all the genetic information required for its replication, but lacks essential codons or all codons of at least one of the genes encoding the viral structural proteins E1, E2, E | 2011-08-04 |
20110189225 | ATTENUATED BACTERIA USEFUL IN VACCINES - The invention provides strains of bacteria, especially enterotoxigenic | 2011-08-04 |
20110189226 | Immunization Compositions and Methods - The present invention provides methods and compositions to induce neutralizing antibodies in mammals to serotypes of dengue virus, measles virus, mumps virus, rubella and/or VZV virus. | 2011-08-04 |
20110189227 | PORCINE CIRCOVIRUS TYPE 2 AND USE THEREOF - Porcine circovirus type 2 (PCV2) having high replication ability in host cells and use thereof. | 2011-08-04 |
20110189228 | Production of Heterologous Polypeptides in Microalgae, Microalgal Extracellular Bodies, Compositions, and Methods of Making and Uses Thereof - The present invention relates to recombinant microalgal cells and their use in heterologous protein production, methods of production of heterologous polypeptides in microalgal extracellular bodies, microalgal extracellular bodies comprising heterologous polypeptides, and compositions comprising the same. | 2011-08-04 |
20110189229 | VACCINE AGAINST HPV - The use of HPV 16 and HPV 18 virus like particles (VLPs) together with a pharmaceutically acceptable excipient, in a vaccine for the prevention of human papillomavirus related disease or infection, wherein the vaccine is formulated for administration according to a two dose regimen consisting of a first dose and a second dose. | 2011-08-04 |
20110189230 | VACCINATION WITH MULTIPLE CLADES OF H5 INFLUENZA A VIRUS - H5N1 influenza viruses isolated from animals and humans since 2003 separate into distinct clades based on hemagglutinin amino acid sequences. According to the invention, multiple clades are used in influenza immunization. Thus there is a prime-boost immunization schedule where a subject receives a priming dose of a first clade of H5 influenza A virus and a boosting dose of a second clade of H5 influenza A virus. There is also an immunogenic composition comprising hemagglutinin antigens from more than one clade of H5 influenza A virus. | 2011-08-04 |
20110189231 | Compositions Comprising Salmonella Porins and Uses Thereof as Adjuvants and Vaccines - Adjuvants comprising OmpC porin, OmpF porin, or a combination thereof, are provided. The adjuvants can be administered to a subject in combination with antigenic material in order to potentiate the immunogenic effect of the antigenic material. Also provided are products comprising antigenic material in combination with OmpC and/or OmpF, including products comprising a pre-formulated vaccine in combination with OmpC and/or OmpF. Further provided is the use of OmpC and/or OmpF to improve the effect of a pre-formulated vaccine. | 2011-08-04 |
20110189232 | RECOMBINANT HUMAN PARAINFLUENZA TYPE 1 VIRUSES (HPIV1s) CONTAINING MUTATIONS IN OR DELETION OF THE C PROTEIN ARE ATTENUATED IN AFRICAN GREEN MONKEYS AND IN CILIATED HUMAN AIRWAY EPITHELIAL CELLS AND ARE POTENTIAL VACCINE CANDIDATES FOR HPIV1 - Two recently characterized live attenuated HPIV1 vaccine candidates, rHPIV1-C | 2011-08-04 |
20110189233 | Recombinant Varicella-Zoster Virus - A recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing recombinant varicella-zoster virus; a vector containing a genomic gene of varicella-zoster virus and BAC vector sequence; cells containing the above vector; a fragment capable of homologous recombination with a genome of varicella-zoster virus; and a nucleic acid cassette containing the BAC vector sequence. For these, there is provided a process for producing recombinant varicella-zoster virus, comprising use of the BAC vector sequence. | 2011-08-04 |
20110189234 | ADENOVIRUS PARTICLES HAVING A CHIMERIC ADENOVIRUS SPIKE PROTEIN, USE THEREOF AND METHODS FOR PRODUCING SUCH PARTICLES - The present invention is concerned with means and methods for producing adenovirus particles comprising a chimeric adenovirus spike protein that essentially lacks a functional knob domain. One aspect of the invention is concerned with a method for producing adenovirus particles comprising providing cells that are permissive for adenovirus replication with an adenovirus vector, with nucleic acid encoding said chimeric adenovirus spike protein and with nucleic acid encoding at least one adenovirus E3 region protein or a functional part, derivative and/or analogue thereof, said method further comprising culturing said permissive cells to allow for at least one replication cycle of said adenovirus virus and harvesting said adenovirus particle. | 2011-08-04 |
20110189235 | Adipogenic Adenoviruses As A Biomarker For Disease - A vaccine composition may be administered to a subject to increase immunity to an adipogenic adenovirus-related cancer. The vaccine composition stimulates the production of adipogenic adenovirus neutralizing antibodies in the subject, which may increase immunity to the adipogenic adenovirus-related cancer in the subject. | 2011-08-04 |
20110189236 | Methods and Compositions for the Display of Polypeptides on the Pili of Gram-Positive Bacteria - Provided herein are methods and compositions for the display of polypeptides of interest on the tip of pili of Gram-positive bacteria. According to the present invention, the polypeptide of interest is amino terminal to a Gram-positive bacterial pilus tip protein or an active variant or fragment thereof, wherein the active variant or fragment comprises a cleaved cell wall sorting signal (CWSS) motif. The Gram-positive bacterium displaying a polypeptide of interest on the tip of pili that are disclosed herein are useful, for example, in methods for immunizing a subject with an antigen and methods for removing contaminants from a composition. | 2011-08-04 |
20110189237 | Therapeutic Agent for Malignant Mesothelioma and Immunostimulant - According to the present invention, a method for treating malignant mesothelioma using REIC/Dkk-3 and a therapeutic agent for malignant mesothelioma comprising REIC/Dkk-3 are provided. A mesothelioma therapeutic agent is provided, comprising the following REIC/Dkk-3 DNA or a vector comprising the DNA as an active ingredient:
| 2011-08-04 |
20110189238 | USE OF A SOLUBLE FORM OF HLA-G IN THE TREATMENT OF ABNORMAL B-LYMPHOCYTE PROLIFERATION - The invention relates to a novel use of the soluble forms of HLA-G in the treatment or prophylaxis of abnormal B-cell proliferation, such as liquid cancers of the B type. | 2011-08-04 |
20110189239 | Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same - Dermal delivery compositions are provided. Aspects of the dermal delivery compositions include the presence of active agent-calcium phosphate particle complexes, where these complexes include uniform, rigid, spherical nanoporous calcium phosphate particles associated with one or more active agents. Also provided are methods of using the compositions in active agent delivery applications. | 2011-08-04 |
20110189240 | MICROENCAPSULATED COMPOSITIONS FOR ENDOLUMINAL TISSUE ENGINEERING - A tissue engineering composition adapted for application to an interior surface of a body lumen of a patient. The composition comprises (a) a carrier medium that is adapted to flow and to stably adhere the composition to the body lumen and (b) microcapsules, which are dispersed within the carrier medium and which contain one or more living cells encapsulated within a coating that includes a biodegradable polymer. The composition promotes growth of the cells on the lumen surface subsequent to application of the composition to the lumen. | 2011-08-04 |
20110189241 | Process For Controlling The Particle Size of A [3-(Trifluoromethyl)Phenyl]-1-Aminopropane Derivative - The invention relates to a process for tightly controlling the particle size of cinacalcet hydrochloride, i.e. a process for preparing large or small crystals of cinacalcet hydrochloride, which yields cinacalcet hydrochloride in a narrow, reproducible and consistent distribution of particles, which hence does not require to reprocess, rework or destroy material of undesired size, which is efficient and cost-effective, and which is suitable for industrial implementation. | 2011-08-04 |
20110189242 | ORAL GALENIC FORM, POLYMER PRODUCTION METHOD AND USE OF SAME - The polymers, according to the invention, comprise a polysaccharide block ( | 2011-08-04 |
20110189243 | PHARMACEUTICAL FORMULATION FOR LOWERING PULMONARY BLOOD PRESSURE - The invention relates to pharmaceutical formulations for reducing pulmonary blood pressure containing micronised ambrisentan, preferably in the form of an intermediate together with a hydrophilising agent. The invention also relates to methods of preparing pharmaceutical formulations containing micronised ambrisentan. | 2011-08-04 |
20110189244 | APPETISING MEDICAMENT FOR ORAL ADMINISTRATION IN SOLID FORM - The invention relates to a coating composition for application to a veterinary pharmaceutical composition for oral administration, by a film coating method, comprising a powder appetising material a binder and a solvent. The invention further relates to a coating method by film coating of a solid veterinary pharmaceutical for oral administration and appetising medicaments for animals comprising a veterinary pharmaceutical composition and an appetising coating arranged around said composition, comprising an appetising material and a binder. | 2011-08-04 |
20110189245 | Smooth, High Solids Tablet Coating Composition - The invention describes a coating composition comprising an effective amount of a water-soluble cellulose ether, a poly(N-vinyl pyrrolidone-co-vinyl acetate) copolymer, a film-forming agent based on D-glucose, and a plasticizer. | 2011-08-04 |
20110189246 | Porous, Dissolvable Solid Substrate and a Cationic Surfactant Conditioner Material - The present invention relates to personal care compositions, especially those personal care compositions in the form of a personal care article that is a porous dissolvable solid substrate. The porous dissolvable solid substrate has a surface resident coating comprising the cationic surfactant conditioner active that can provide a conditioning benefit. | 2011-08-04 |
20110189247 | Porous, Dissolvable Solid Substrate and a Surface Resident Coating of Cationic Surfactant Conditioner - The present invention relates to hair care compositions, especially those hair care compositions in the form of a hair care article that is a porous dissolvable solid substrate. The porous dissolvable solid substrate has a surface resident coating comprising the cationic surfactant conditioner active that can provide a conditioning benefit. | 2011-08-04 |
20110189248 | Home And Personal Care Compositions - Provided are home and personal care compositions comprising a cationic hydrophobically modified galactomannan ether and a silicone, where the cationic hydrophobically modified galactomannan ether have a cationic degree of substitution (DS | 2011-08-04 |
20110189249 | Low pH Retinoid Topical Compositions - A low pH composition containing a retinol and a method for treating skin is disclosed. The composition contains (a) a retinoid and (b) an active acid, like an alpha-hydroxy acid or a beta-hydroxy acid, and has a pH of less than 5. | 2011-08-04 |
20110189250 | GREEN APPROACH IN METAL NANOPARTICLE-EMBEDDED ANTIMICROBIAL COATINGS FROM VEGETABLE OILS AND OIL-BASED MATERIALS - The present invention generally relates to a method of making nanoparticles and uses thereof. In particular, the invention relates to methods of making metal nanoparticles (MNPs). The invention also relates to antimicrobial uses of the nanoparticles. | 2011-08-04 |
20110189251 | COMPOUNDS AND COMPOSITIONS FOR THE CONTROL OF PESTS - A method of killing a pest such as an arthropod or invertebrate pest comprises contacting an active agent such as 2-undecanone to said pest in an amount effective to kill said pest. In some embodiments, the contacting step is carried out by applying the active agent such as 2-undecanone or composition containing the same to a plant or animal (e.g., a human, or other mammalian species such as dog, cat, horse, pig, cow sheep, goat, etc.) in an amount substantially non-toxic to said plant or animal. In some embodiments, the contacting step is carried out by applying said active agent such as 2-undecanone as a composition (e.g., an aqueous composition) comprising said 2-undecanone in combination with a soy methyl ester. The composition may be in the form of an emulsion (including microemulsions). | 2011-08-04 |
20110189252 | PHARMACEUTICAL COMPOSITIONS COMPRISING LIGNANS AND THEIR DERIVATIVES FOR TREATING HYPERPLASTIC DISEASES - The present invention relates to a pharmaceutical composition comprising specific compounds which may be obtained from | 2011-08-04 |
20110189253 | BIOMATERIAL COMPOSITION AND METHOD - The disclosure is directed to a composition includes a macromer having a polymeric backbone comprising units with a 1,2-diol or 1,3-diol structure and at least two pendant chains bearing crosslinkable groups, an amphiphilic comonomer, and a crosslinking initiator, wherein the composition has a setting time of less than about 3 minutes. The disclosure is further directed to a kit and a method of making the above-mentioned composition. | 2011-08-04 |
20110189254 | SURGICAL GRAFTS FOR REPAIRING CHONDRAL DEFECTS - An implant containing a collagen matrix embedded with chondrocyte-like cells, its use in repairing a chondral defect, and a method of preparing the implant. | 2011-08-04 |
20110189255 | DRUG-ELUTING STENTS FOR ADENOSINE RECEPTOR MODULATION - Drug eluting stents (DES) useful for the treatment of restenosis are described. The stents comprise biocompatible polymers and adenosine receptor modulators. | 2011-08-04 |
20110189256 | REDUCTION OF INFECTION ASSOCIATED WITH MEDICAL DEVICE - Anti-infective articles capable of preventing infection associated with implantation of medical devices include low levels of anti-infective agents, may cover only a fraction of the portion of the medical device and be effective, or may rapidly elute anti-infective agent, without sustained elution, and still be effective. | 2011-08-04 |
20110189257 | NANOPARTICLE BASED THERAPY FOR AGGREGATING MUCIN - There are provided compositions and methods to aggregate mucus using a plurality of positively charged nanoparticles. There are also provided compositions and methods for inducing contraception in the subject. | 2011-08-04 |
20110189258 | METHOD AND COMPOSITIONS FOR INHIBITION OF DOUBLE STRANDED DNA VIRUSES - A method of inhibiting double-stranded DNA virus infection is disclosed. In one embodiment, the method involves exposing a papillomavirus to an effective amount of an inhibitor selected from the group of G1, S, G2, and M cell cycle inhibitors. In another embodiment, the method involves administering an inhibitor selected from the group of G1, S, G2, and M cell cycle inhibitors to a susceptible tissue or cell. | 2011-08-04 |
20110189259 | MULTIDIRECTIONAL MUCOSAL DELIVERY DEVICES AND METHODS OF USE - The present invention relates to a pharmaceutical dosage form for transmucosal delivery of an active agent to two or more mucosal surfaces. The dosage form is presented as a transmucosal delivery device. The devices of the invention may include at least two mucoadhesive surfaces. The devices may further include an intermediate layer disposed between the mucoadhesive layers. The pharmaceutical can be incorporated in any one or all of the mucoadhesive layers or the intermediate layer. Upon application, the device adheres to at least two surfaces, providing transmucosal delivery of the drug to at least two surfaces. | 2011-08-04 |
20110189260 | USE OF ZINC CHELATORS TO INHIBIT BIOFILM FORMATION - A method is provided for inhibiting formation of a biofilm of bacteria, the method including contacting the bacteria with an effective amount of at least one zinc chelator, wherein the bacteria contain at least one zinc adhesion module, whereby formation of the biofilm is inhibited. A method for inhibiting biofilm formation on a device and a topical pharmaceutical composition for the inhibition of biofilm formation are also provided. | 2011-08-04 |
20110189261 | TRANSDERMALLY ABSORBABLE PREPARATION - Disclosed is a transdermally absorbable preparation in which the crystallization of a medicinal agent can be prevented even when the medicinal agent has poor solubility in a base material and is contained in the base material at a high concentration, and which exhibits excellent long-term stability and transdermal absorbability of the medicinal agent. By adding a complex of an organic acid and an organic acid salt and a medicinal agent to a base material, it becomes possible to produce a transdermally absorbable preparation in which the crystallization of the medicinal agent can be prevented and which has excellent preparation properties and transdermal absorbability. Also disclosed is use of a complex of an organic and an organic acid salt for preventing the crystallization of a medicinal agent in a transdermally absorbable preparation. | 2011-08-04 |
20110189262 | Methods and Compositions for Reducing Systemic Toxicity of Vectors - A method for reducing leakage of a delivery formulation from a target tissue via a damaged blood vessel during and after administration of the delivery formulation is provided. The method includes the steps of: (a) providing a delivery formulation comprising a blocking agent and one or more vectors encoding one or more polypeptides, wherein the delivery formulation is in a liquid form; and (b) administering the delivery formulation to a target tissue in a subject, wherein the administering results in the viscosity of the blocking agent increasing to at least about 100 cP, whereby leakage of the delivery formulation from the target tissue either during or after administration of the delivery formulation is reduced. | 2011-08-04 |
20110189263 | PEPTIDES THAT TARGET DORSAL ROOT GANGLION NEURONS - The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy. | 2011-08-04 |